Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

DiaMedica Therapeutics (DMAC) Tax Provisions (2018 - 2026)

DiaMedica Therapeutics filings provide 9 years of Tax Provisions readings, the most recent being $7000.0 for Q1 2026.

  • Quarterly Tax Provisions rose 16.67% to $7000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $29000.0 through Mar 2026, changed 0.0% year-over-year, with the annual reading at $28000.0 for FY2025, 6.67% down from the prior year.
  • Tax Provisions hit $7000.0 in Q1 2026 for DiaMedica Therapeutics, down from $10000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $22000.0 in Q4 2023 and bottomed at $6000.0 in Q1 2025.
  • Average Tax Provisions over 5 years is $8000.0, with a median of $7000.0 recorded in 2022.
  • The largest annual shift saw Tax Provisions skyrocketed 214.29% in 2023 before it plummeted 59.09% in 2024.
  • DiaMedica Therapeutics' Tax Provisions stood at $7000.0 in 2022, then skyrocketed by 214.29% to $22000.0 in 2023, then tumbled by 59.09% to $9000.0 in 2024, then grew by 11.11% to $10000.0 in 2025, then dropped by 30.0% to $7000.0 in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Tax Provisions are $7000.0 (Q1 2026), $10000.0 (Q4 2025), and $6000.0 (Q3 2025).